Investors

Medivir to present data on additive efficacy of fostrox in triple combination with anti-PD1 and kinase inhibitor in nonclinical tumor models at AACR

First patient dosed in the phase 2a part of Medivir's study with fostrox in combination with Lenvima

Medivir to present at the Stockholm Corporate Finance Life Science Day